Fluorouracil News and Research

RSS

Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.

New system personalizes chemotherapy doses for cancer patients

When cancer patients undergo chemotherapy, the dose of most drugs is calculated based on the patient's body surface area. This is estimated by plugging the patient's height and weight into an equation, dating to 1916, that was formulated from data on just nine patients.

24 Apr 2024

KFF Health News' 'What the Health?': The Supreme Court and the abortion pill

In its first abortion case since the overturning of Roe v. Wade in 2022, the Supreme Court this week looked unlikely to uphold an appeals court ruling that would dramatically restrict the availability of the abortion pill mifepristone.

28 Mar 2024

Overdosing on chemo: A common gene test could save hundreds of lives each year

One January morning in 2021, Carol Rosen took a standard treatment for metastatic breast cancer. Three gruesome weeks later, she died in excruciating pain from the very drug meant to prolong her life.

26 Mar 2024

Puffed-up MOFs show improved performance as drug-delivery vehicles

The spongelike structure of metal organic frameworks (MOFs) allows these polymers to possibly carry and deliver a range of therapeutic compounds.

27 Jan 2024

Fecal microbiota transplantation boosts survival in metastatic colorectal cancer treatment

A recent study in eClinicalMedicine found that fecal microbiota transplantation, combined with fruquintinib and tislelizumab, significantly improved survival rates in patients with microsatellite stable metastatic colorectal cancer, showing manageable safety and notable increases in progression-free and overall survival.

15 Nov 2023

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

23 Aug 2023

Researchers investigate the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma

Researchers investigated the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma.

31 Jul 2023

Four-drug chemotherapy regimen provides longer overall survival for metastatic pancreatic ductal adenocarcinoma

A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma.

20 Jan 2023

Novel cancer-fighting nanoparticles co-deliver a chemotherapy drug and immunotherapy

University of Pittsburgh researchers have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, according to a new Nature Nanotechnology study published today.

24 Nov 2022

Fermented dairy products can improve gut mucosal immunity

In a recent study published in the journal Immunology Letters, researchers assessed the role of fermented dairy products and dairy starters in modulating gut mucosal immunity.

3 Nov 2022

Are men or women impacted more by adverse reactions to prescription drug treatments?

Recently, researchers presented an overview of sex-based differences in adverse drug reactions (ADRs) based on epidemiology, technique, and underlying mechanism data.

11 Oct 2022

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with PD-L1 expression of at least one percent. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in two early benefit assessments whether these two combinations have an added benefit for patients in comparison with chemotherapy alone.

8 Aug 2022

Treatment of precancerous anal growths in HIV patients decreases the progression to anal cancer

A team of researchers, including LSU Health New Orleans Infectious Diseases and Microbiology professor Michael Hagensee, MD, PhD, has shown for the first time that treating precancerous anal growths called high-grade squamous intraepithelial lesions (HSILs) in persons living with HIV significantly decreased the progression to anal cancer.

15 Jul 2022

New liquid biopsy assay enables prediction of treatment response in patients with esophageal cancer

Biomarkers are like the X on a treasure map, but instead of indicating the location of unearthed riches, they indicate an individual's health status.

16 Jun 2022

Chemical synthesis, properties, and molecular modeling studies of spiro-indole compounds

In a recent study under review at the Scientific Reports journal and currently posted to the Research Square* preprint server, researchers synthesized and evaluated the antitumoral (against several cancer cell lines) and antiviral [against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] properties of 3-spiro-indolin-2-ones.

15 Jun 2022

Reducing mucin secretion provides a way to control chemoresistance of colorectal cancers

Drugs which are commonly-used as the first line of treatment for colorectal cancer cause the tumor cells to oversecrete proteins known as mucins, according to a new study published today in the journal eLife.

9 Feb 2022

Researchers identify new drug that makes pancreatic cancer cells more vulnerable to chemotherapy

Researchers at Washington University School of Medicine in St. Louis have identified a drug compound that makes pancreatic cancer cells more vulnerable to chemotherapy.

1 Dec 2021

Researchers compare transcriptomic and cytokine responses of colorectal cancer cells

Oncotarget published "Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells" which reported that there was an increase in IL-8 by oxaliplatin and increase in ferritin by cisplatin which may contribute to cancer cell survival.

29 Sep 2021

Open-access database could speed up repurposing of old drugs as new treatments

Researchers have created a new open-access database of information on drug candidates and how they are metabolized by the body, which could help speed up the repurposing of old drugs as new treatments.

3 Aug 2021

Drug sensitivity of hepatocellular cancer cells may provide new insights on tumor biology

Oncotarget published "Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells" which reported that this study aimed to investigate whether Hepatocellular Cancer (HCC) cells cultured in more native conditions have an altered phenotype and drug sensitivity compared to those cultured in standard conditions.

8 Jun 2021